Management Board
of MorphoSys AG

Dr. Simon Moroney

Chief Executive Officer
» Excellent progress over the last year means that today our pipeline is broader and more mature than ever before. The first therapeutic antibodies are nearing market approval, bringing us closer to a product-based revenue stream. Meanwhile, our proprietary development portfolio is expanding and the two most advanced programs are approaching decisive stages of clinical development. Across our entire pipeline, we see many programs with outstanding therapeutic potential, to the benefit of all of our stakeholders, not least the patients who they will help. «
Dr. Simon Moroney
Chief Executive Officer

Jens Holstein

Chief Financial Officer
» With financial resources of close to EUR 300 million at year-end 2015, MorphoSys continues to operate from a position of strength. Our solid financial base has been the foundation for MorphoSys’s successful develop­ment over the years, allowing us to continue making targeted invest­ments and grow the Company’s value without losing sight of our prudent and efficient use of resources. «
Jens Holstein
Chief Financial Officer

Dr. Marlies Sproll

Chief Scientific Officer
» During 2015, our product pipeline became broader and more mature than ever before. Our partnered programs are on the cusp of reaping the first rewards of our longtime efforts. In 2016, Novartis’s bimagrumab and Janssen’s guselkumab will be the first HuCALHuCAL: Human Combinatorial Antibody ­Library; proprietary antibody ­library enabling rapid generation of ­specific human antibodies for all ­applications antibodies to deliver phase 3 data, and we may see the first MorphoSys antibody reach the market before year-end – another exciting year is lying ahead. «
Dr. Marlies Sproll
Chief Scientific Officer

Dr. Arndt Schottelius

Chief Development Officer
» In 2015 we generated encouraging clinical data with our proprietary cancer agents. We are now expanding these programs and moving them, step-by-step, towards approval and commercial viability. At the center of this campaign will be the start of three combination studies with our most advanced antibody MOR208 in DLBCLDLBCL: diffuse large B cell lymphoma, a subform of NHL and CLLCLL: Chronic lymphocytic leukemia; most common type of cancer of the blood and bone marrow, affecting the B cells in 2016, one of which is expected to progress directly into a pivotal study next year, marking yet another major milestone in the history of MorphoSys. «
Dr. Arndt Schottelius
Chief Development Officer
Top Next